HFDOX
Latest Information Update: 11 Jul 2023
Price :
$50 *
At a glance
- Originator HighField Biopharmaceuticals
- Class Antineoplastics
- Mechanism of Action Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 11 Jul 2023 Discontinued - Preclinical for Cancer in China (Parenteral) (HighField Biopharmaceuticals pipeline, July 2023)
- 31 May 2022 Preclinical trials in Cancer in China (unspecified route) (HighField Biopharmaceuticals pipeline; May 2022)